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Abstract 
Treatment of the injured joint with rhPRG4 is based on recent observations that 
inflammation diminishes expression of native PRG4. Re-establishing lubrication between 
pressurized and sliding cartilage surfaces during locomotion promotes the nascent 
expression of PRG4 and thus intra-articular (IA) treatment strategies should be supported 
by pharmacokinetic evidence establishing the residence time of rhPRG4. A total of 21 
Yucatan minipigs weighing ~55 Kg each received 4 mg of 131I-rhPRG4 delivered by IA 
injection 5 days following surgical ACL transection. Animals were sequentially euthanized 
following IA rhPRG4 at 10 mins (time zero), 24, 72 hrs, 6, 13 and 20 days later. The decay 
of the 131I-rhPRG4 was measured relative to a non-injected aliquot and normalized to the 
weight of cartilage samples, menisci and synovium, and known cartilage volumes from 
each compartment surface obtained from representative Yucatan minipig knees. Decay 
of 131I-rhPRG4 from joint tissues best fit a two-compartment model with an  half-life (t1/2) 
of 11.28 hours andhalf-lifet1/2) of 4.81 days.  The tibial and femoral cartilage, meniscii 
and synovium retained 7.7% of dose at 24 hrs. High concentrations of rhPRG4 were found 
in synovial fluid (SF) that was non-aspiratable and resided on the articular surfaces, 
removable by irrigation, at 10 mins following 131I-rhPRG4 injection. Synovial fluid K21 
exceeded K12 and SF t1/2 was 28 days indicating SF is the reservoir for rhPRG4 following 
IA injection.  Clinical Significance: rhPRG4 following IA delivery in a traumatized joint 
populates articular surfaces for a considerable period and may promote the native 
expression of PRG4. This article is protected by copyright. All rights reserved 
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Introduction 
 
Osteoarthritis (OA) 1leads to functional disability and a reduced quality of life2. 
Abnormal biomechanics is a major risk factor in disease progression and joint tissue damage3. 
Post-traumatic osteoarthritis (PTOA) is a syndrome of joint degeneration and pain that develops 
after joint injuries4; 5.   Treating joint pain alone may actually exacerbate PTOA7; 8 since the pain 
response is adaptively interfering with locomotion, and unloading the affected joint. New 
therapeutic approaches that mitigate the risk of developing PTOA, particularly for young patients 
with meniscal and anterior cruciate ligament (ACL) tears6 are needed. 
Five different research groups have tested native9, recombinant human lubricin 
(rhPRG4)10-12 or lubricin mimic biomolecules13; 14 by re-introducing these into rodent joints after 
injury in the effort to retard cartilage loss. The inflammation associated with meniscal and ACL 
injuries is thought to downregulate PRG4 expression15; 16.  Rats that underwent medial 
meniscectomy11 or  ACL transection9; 17  treated with repeated or single dose intra-articular (IA) 
rhPRG410 showed a chondroprotective effects measured by improved histology. Two studies 
showed a reduction in urine levels of CTX-II—a classical biomarker of cartilage degradation10; 17. 
Another study in ACL transected rat knees  showed an improvement in the radiographic outcome 
following supplementation with lubricin18. Chondroprotective results were also evident in rats that 
underwent forced exercise17 and in mice where a helper-dependent adeno viral vector expressing 
Prg4 prevented development of PTOA in mice19. Most recently we showed in large animals 
following destabilization of the medial meniscus (DMM)12 that chondral lesions were smaller and 
synovial fluid (SF) CTX-II levels were significantly lower, 5.5 months later following IA rhPRG4. 
Lubricin supplementation decreases the number of apoptotic chondrocytes17; 20; 21 and increases 
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
5 
This article is protected by copyright. All rights reserved 
 
native lubricin expression10. Elevated joint friction in Prg4 null mice22 also showed diminished 
chondrocyte density23.  A concern about lubricin supplementation is whether rhPRG4 has a 
favorable pharmacokinetic profile that would lead to its continued presence and enable tribological 
protection. 
 
The half-life of radiolabeled truncated lubricin is 4.5 hours in a medial meniscectomized 
rat24. However, this value must be reconciled with radioactivity still present on the articular surface 
up to 28 days following IA injection. Lubricin persists in traumatized cartilage25 and contributes 
to protect joints from mechanical injury and may mitigate PTOA.  Our current focus is to gather 
data in a large animal model, particularly at early time points in an injury model, to enable 
pharmacokinetic modeling that will be predictive of lubricin residence time in the human knee by 
allometric scaling26. Transection of the ACL was chosen in a large animal model in this study since 
lubricin levels in patients with an untreated ACL injury require a year to return to normal27 and 
leads to an aggressive PTOA, dependent on early alterations in the cartilage matrix28. 
 
METHODS 
Animals 
The study was conducted at University of Guelph, Ontario, Canada and used purpose-bred  
castrated male and female Yucatan mini-pigs (N=21) weighing 50-60 kg. All porcine were 
 adolescent animals, born within 2 weeks of each other and were 9 months old at study conclusion. 
Each animal underwent hematological, physical and musculoskeletal examinations upon arrival 
from S&S Farms (Ramona, CA). Seven (7) days were permitted for acclimatization prior to 
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surgery during which the animals were housed in pairs or small groups depending on behavior. 
Animals were maintained in controlled environmental facilities at 20oC and light/dark cycle 
determined by ambient lighting. The study protocol was approved by the institutional animal care 
and use committee and conducted in accordance with the Canadian Council on Animal Care 
guidelines. 
Manufacture of rhPRG4 
The expression of rhPRG4 by CHO-M cells has been described previously29. CHO-M cells were 
transfected with the full-length human PRG4 gene resulting in a 1404 amino acid PRG4 (Lubris, 
LLC, Framingham, MA). Manufacturing was performed by Peregrine Pharmaceuticals, Inc., 
Tustin, CA) under pre-GMP conditions.  The presence of O-linked glycosylations comprised of 
(β1,3)Gal-GalNAc was previously confirmed by Western blot30; 31 and concentration was 
established by ELISA31. 
Labelling of rhPRG4 with 131I 
rhPRG4 was radiolabelled with 131I in 0.1M NaOH (Perkin Elmer Health Science, Canada, Inc) 
using the iodine monochloride method. Radiolabelled rhPRG4 was passed through a column 
containing AG1-X4 resin (Bio-Rad, Hercules, CA) to remove free 131I.  The trichloroacetic acid 
test was performed to determine unbound 131I in the solution which did not exceed 8% (w/w). Vials 
containing 4 mg of 131I-rhPRG4 in 3 ml PBS carrier with 32 Ci radioactivity were prepared for 
animal injection. 
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Surgical and Anesthesia Procedures 
Using general anesthesia and aseptic technique mini-pigs underwent arthroscopic ACL ligament 
transection of the right knee joint followed by the IA administration of 4 mg of 131I-rhPRG4 5 days 
later. At the time of arthroscopy joint cavity irrigation was limited to 120 ml of sterile physiologic 
saline. Radiolabeling of rhPRG4 (Lubris, LLC) was performed at McMaster University, and sent 
the same day by courier to Ontario Veterinary College, University of Guelph. The 131I-rhPRG4 
was used within the day of arrival. The left knee was unaffected. There were no uninjected surgical 
control animals. 
On the day of the surgery porcine were pre-medicated with acepromazine (0.2 mg/kg), atropine 
(0.05 mg/kg) and buprenorphine (0.02 mg/kg) given intramuscularly (IM). Anaesthesia was 
induced with ketamine (20 mg/kg) and mask-ventilated (or intubated with an endotracheal tube) 
with a 2% isoﬂurane O2 mixture. Aspiration of SF from both knees was attempted prior to surgical 
entry of the joint.  Postoperative analgesia consisted of peri-articular subcutaneous (sc) injection 
of diluted bupivacaine (0.25%, 0.05-0.1 mL, dose < 1 mg/kg) and sc buprenorphine (0.05 to 0.1 
mg/kg) every 4-6 hours as needed for up to 72 hours.  
On day 5 post-surgery (designated D=0) all 21 pigs were sedated with acepromazine (0.2 mg/kg) 
and ketamine (20 mg/kg) given IM to induce dissociative anesthesia, followed by an IA injection 
of 4 mg 131I-rhPRG4 into the right knee. Flexion and extension of the right knee was performed 
for 5 minutes post injection to ensure distribution of the 131I-rhPRG4.  
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Tissue Harvesting and Preparation of Counting for Radioactivity Decay 
Minipigs were euthanized at specific timepoints determined a priori illustrated in Fig 1 for 
collection of tissues. Animals were euthanized by sedation with acepromazine and ketamine (as 
above) followed by an overdose of pentobarbitol (100 mg/kg) IV via an ear vein. Right knees 
were collected and SF was collected by aspiration. Upon gross dissection, cartilage surface 
irrigation with 5 ml of PBS was performed and recovered. Partial thickness cartilage specimens 
were excised from the medial femoral, medial tibial, lateral femoral, lateral tibial and patellar 
surfaces. The medial and lateral menisci were collected. Anterior and posterior synovial lining 
tissue, the pre-femoral lymph node, liver tissue and urine was also collected. Each of these 
tissues were weighed, and then held at 4˚C while transported to McMaster University for 
gamma counting within 3 hours of collection. A 24 hour urine collection was not conducted since 
metabolic cages were not available. 
Gamma Counting 
The amount of 131I-rhPRG4 remaining in tissues was measured using a Wizard 3 1480 Automatic 
Gamma Counter (Perkin Elmer, Woodbridge, ON, Canada). The gamma radiation counts were 
then converted to rhPRG4 amounts based on the counts of a non-injected 131I-rhPRG4 standard 
solution that was stored at McMaster University. 
Prior Yucatan Minipig Cartilage, Meniscus and Synovium Total Mass Measurements 
Four previously frozen unoperated Yucatan mini-pig left knee joints were disarticulated into 
separate segments that included the distal femur, proximal tibia and patella.  The entire joint 
capsule was kept attached to the patella for subsequent soft tissue studies. The medial and lateral 
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menisci were excised and weighed using an analytical balance. A GE eXplore Locus CT scanner 
(Schenectady, NY) was used to image the bone and soft tissue segments in humidified air. An 18 
minute long 45 micron resolution protocol32  resulted in 720 slices comprised of isotropic voxels. 
Slices were compiled and subsequently realigned in a true frontal plane. Image manipulation and 
analysis was done using Microview 2.5 (Parallax Innovations, Ilderton, ON, Canada). Articular 
cartilage volume and surface area were measured by outlining cartilage in thresholded frontal plane 
image slices using the advanced region of interest (ROI) (spline) tool. Three-dimensional ROIs 
were compiled and voxel counts from isosurface projections were used in calculation of area and 
volume (Figure 2). Separate ROIs were created for the medial and lateral condyles, medial and 
lateral tibial plateaus and patella cartilage plates.  Cartilage mass was calculated by volume x 1.1 
gm/cc based on volume displacement trials of porcine articular cartilage. 
Synovial membrane mass was calculated by first identifying the geographic distribution of 
synovial membrane in normal mini-pig knees as determined by microCT imaging of the entire 
Lugol’s iodine-stained joint capsule in Ringer’s solution. Synovial tissue mass was determined 
from harvested normal unoperated joints by dissecting synovial fronds from the underlying joint 
capsule while the tissue was immersed in Ringer’s solution which allowed the synovial tissue to 
float and adopt a three-dimensional villus profile. Areas of synovial lining tissue were weighed 
after collection using an operating microscope and micro-instruments. 
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Pharmacokinetic Calculations 
The individual knee tissue concentrations of total radioactivity were normalized to a gram of tissue 
and the total amount of rhPRG4 per tissue was calculated using the total mass of individual knee 
tissues. The percent of rhPRG4 dose detected at each time point: zero (10 mins), 24, 72 hrs, 6, 13 
and 20 days was calculated after a single IA dose of 131I-rhPRG4 of 4 mg/knee. The area under the 
blood concentration-time curves (AUC) was calculated using the trapezoidal rule up to the last 
measured concentration, Clast. To the latter AUC was added Clast/β to calculate AUC0-∞. The 
parameters were determined for each individual animal and their average was calculated.  
The total radioactivity counts of 131I-rhPRG4 (expressed as percent of total dose) at each time point 
was calculated and fitted to two compartment model using Phoenix WnNonlin version 64 
(Pharsight Corporation, Sunnyvale, CA, USA). The percent of total dose in cartilage, menisci and 
synovium at different time points were fitted using least square regression with either 1/y or 1/y2 
weighting factors to two compartmental model (Ct = Ae
-αt + Be-βt) where Ct counts (as % dose) at 
time t were weighted as the inverse of the Ct. Pharmacokinetics parameters of blood concentrations 
of 131I-rhPRG4 (µg equivalent/mL) at each time point were calculated for each individual animal 
after fitting the concentrations time curve to a two compartment model.  
Western Blotting of PRG4 in SF and Joint Lavage Samples, and IL-1 ELISA 
SDS-PAGE electrophoresis of undiluted samples on pre-cast 4-12% gradient gels (ThermoFisher 
Scientific, Waltham, MA) and transfer to nitrocellulose was performed as described previously31. 
Polyclonal antibody 1752 (ABPRO, Woburn, MA, USA) that reacts with the epitope 
FESFERGRECDCDAQCKKYDK in the N-terminus of PRG433 was used at 1:1000 dilution 
with 5% bovine serum albumin in PBST.  Membranes were incubated with IRDye goat anti-
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rabbit IgG at 1:10,000 dilution for 1 hr at RT with shaking. Levels of IL-1 were measured on 
undiluted samples using a commercially available kit #PLB00B (R&D Systems, Minneapolis, 
MN). 
Blot Imaging and Densitometric Analysis 
The blots were imaged with LI-COR Odyssey (LI-COR Biosciences, Lincoln, NE, USA) imaging 
system with 800 or 700 CW according to manufacturer’s instruction. NIH image J 
(https://imagej.nih.gov/ij/) was used for chemiluminescent band analysis (NIH, Bethesda, MD, 
USA). Lanes were compared to a -actin standard and densitometrically normalized to a LI-COR 
anti-β actin monoclonal antibody #926-42210. Densitometric standards were established by 
imaging known amounts of rhPRG4 solubilized in normal porcine SF in different lanes of a blot 
simultaneously. The detectable limit of rhPRG4 concentration was 10 g/ml.  
 
Tissue Processing and Immunohistochemistry 
Following gamma counting at the time of sacrifice, all knee joint tissues were fixed in 10% 
formalin (PROTOCOL™, Fisher, Waltham, MA, USA). After 4 months to allow for sufficient 
radioactive decay, samples were transported under United States Department of Agriculture permit 
#132894.  Samples were decalcified using 0.48 M EDTA, with adjusted pH of 7.1 with ammonium 
hydroxide at 4°C. Embedded tissues were sectioned with a thickness of 10µm. 
Sections were probed for surface accumulation and nascent expression of PRG4 within 
chondrocytes using monoclonal antibody 9G331 (EMD Millipore; Darmstadt, Germany) which 
reacts with the mucin domain of PRG4 using methods described previously25.  
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Statistical Methods  
Data were reported as mean ± standard deviation (SD) unless otherwise indicated. Descriptive 
statistical analyses were performed using Prism 6 software (GraphPad, La Jolla, CA). 
RESULTS 
Study Conduct and Tissue Recovery 
This uncontrolled study was conducted over 16 months in groups of 6, 12 and 3 porcine due to 
animal availability. No adverse events occurred. Three animals were removed from the analysis 
since they evidently did not receive IA rhPRG4 since radioactivity was undetected in the SF 
from euthanized animals #39 and #91 at time point 10 minutes (time zero) and animal #86 at 24 
hrs. In these animals, the principal radioactivity was recovered in either the proximal lymph node 
or in the urine. Across the remaining 18 porcine at the time point of 10 mins, an average of 
32.0% of dose was located in the cartilage and synovial knee tissues, 20.7% in synovial fluid, 
1.2% on the ACL stump, 0.09% in the proximal lymph node, 9.5% in liver and 35.4% in the 
lavage of the joint surfaces. Another lavage at 24 hrs only recovered 0.064% of dose suggesting 
that a majority of the rhPRG4 was present in the SF or fully adherent to articular and synovial 
surfaces. rhPRG4 was primarily excreted in the urine and was not significantly present in 
adjacent lymph nodes in the 18 animals that received the IA injection correctly. Tissue 
recoveries were not conducted for the first group of 6 animals allocated to time points 6,13 and 
20 days post IA injection. 
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Elimination of I131-rhPRG4 and Akaike Information Criterion (AIC) model fitting 
Figure 3a shows the distribution and elimination of the percent dose of total radioactivity of the 
knee which included all joint tissues, the lavage fluid and SF which in aggregate accounted for 
89.4% of total dose. At 24 hrs after injection, 7.7% of the total instilled dose of 131I-rhPRG4 is 
resident in the joint. Radioactivity is still present on days 13 and 20 suggesting that the complete 
elimination of 131I-rhPRG4 is delayed. A two-compartment elimination model, using AIC, best 
fit these data from the 18 porcine using counts from cartilage, meniscii and synovial tissue which 
accounted for 33% of dose (Figure 3b).  The porcine knee joint modeled with this two-
compartment elimination model shows that the  half-life (t1/2phase is 11.28 hours and the t1/2 
is 4.81 days long (Figure 3c and 3d).  
Different modeling permutations of tissue counts from cartilage, meniscii and synovium, SF and 
cartilage surface lavage were analyzed in Table 1 to identify tissues and/or fluids with maximal 
t1/2 and t1/2. Permutations that included counts from cartilage lavage had a shorter t1/2 and did 
not appear different than those containing cartilage tissues. Table 1 also indicates that t1/2 and 
t1/2 values did not lengthen when considering only counts from cartilage, meniscii and synovial 
tissue. Permutations that included SF counts maximized t1/2 to a maximal time of 28 days. 
Calculation of K12 and K21 (Table 1) for cartilage, meniscii, synovial tissues and SF shows that 
K21 > K12 for SF and synovium indicating that 131I-rhPRG4 was more likely to reside in SF or 
on synovial surfaces.  Cartilage and other tissues, with and without lavage all showed K21< K12 
indicating that 131I-rhPRG4 was more likely retained on cartilage and meniscii. The long SF t1/2 
value of 28 days and the K21/K12 ratio greater than unity support that SF is the reservoir for 
PRG4.  
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The blood concentrations of total radioactivity of 131I-rhPRG4 also showed a two-compartment 
profile with the highest concentrations shown at 10 minutes after dose (5.8±7.1µg 
equivalent/mL).  Lubricin was eliminated from the systemic circulation with a mean total 
clearance of 21.54±4.18 mL/day/kg and a t1/2of 6.48 hours and t1/2 of 15.88 days.  However, 
the mean systemic exposure represented by total area under the blood concentrations time curve 
(AUC 0-∞) was < 15% of the total area under the knee tissue concentrations curve of 
131I-rhPRG4 
(3.38±0.65 vs 26.32±0.47 µg equivalent day/mL). Following the IA administration of 131I-
rhPRG4 9.5% of total dose was found in the liver after 10 mins which decreased to 5.6% and 
0.36% after 1 and 13 days, respectively. However, no radioactivity was detected on day 20.   
Tibial-femoral Joint Compartmentalization of rhPRG4 
Tibial cartilage and synovial membrane surfaces appeared to contain relatively larger amounts of 
131I-rhPRG4 at time 0 (Figure 4a). By day 1 synovial surfaces appeared to contain relatively 
larger amounts of 131I-rhPRG4. By day 13 and 20, cartilage surfaces showed the greatest relative 
amounts of 131I-rhPRG4 (Figure 4b). In comparing the proportion of 131I-rhPRG4 localizing to 
the femoral and tibial cartilage in medial and lateral joint compartments we observed that 
initially 131I-rhPRG4 localized more to the tibial cartilage surfaces and equally to both 
tibiofemoral joint compartments (Figure 5a). Towards the end of the concentration-time profiles 
studied at day 20, the lateral joint compartment and femoral cartilage retained a greater relative 
percentage of recoverable 131I-rhPRG4 (Figure 5b). 
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Cartilage Surface Lavage and Western Blots of rhPRG4 and Porcine PRG4 
Both rhPRG4 and native porcine PRG4 were detected on Western blots of recovered cartilage 
surface lavages (Figure 6a). The different molecular weights of detectable rhPRG4 (apparent 
MW~300 kDa) and porcine PRG4 (MW~180 Kda) enabled the densitometric measurement of 
rhPRG4 relative to porcine PRG4. Figure 6a shows that rhPRG4 was detectable up to 13 days after 
IA injection. Semi-quantitative analysis in Figure 6b indicates that rhPRG4 levels are initially high 
at time zero, decreased at 24-72 hrs, and were near zero by day 20. By contrast, the relative 
amounts of porcine PRG4 increased from day 3 to day 13. 
 
Immunohistochemistry of Total PRG4, and IL-1 Levels 
The observation that the amount of rhPRG4 was decreasing as the relative amount of native PRG4 
increased is supported by immunohistochemistry using mAb 9G3 for total PRG4 on the articular 
surfaces (Figure 7). The total detectable amount of surface PRG4 diminished from day 1 to day 
20. Near the time of IA delivery at 10 minutes there is some immunoreactivity at the articular 
surface but significantly less than cartilage from animals sacrificed after 24 hours likely indicating 
that sometime was needed for rhPRG4 to interact with the articular surface and colocalize with 
native porcine PRG4. Superficial zone chondrocyte immunopositivity for PRG4 became more 
observable at days 6 and 13 suggesting that endogenous production of porcine PRG4 was increased 
during the time course of the study. IL-1 at time 0 in surface lavage was 319.8±365.8 pg/ml (N=3) 
and 74.8±81.8 pg/ml in SF (N=3). At 24 hrs two porcine had SF levels of 88.7 and 34.8 pg/ml. IL-
1 levels were below detectable limits for porcine SF and lavaged samples over the remaining 
time points with the exception of 34.1 pg/ml for a SF sample at 20 days. 
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DISCUSSION 
Recombinant human PRG4 is surface active and recapitulates the ability of natural lubricin to coat 
biological surfaces and provide both anti-adhesive34-36 and lubricating activity29. Lubricin forms 
end-grafted brushes37-39 that provide steric hindrance against a like-covered apposing articular 
surface and structures hydration shells vis-à-vis extensive O-linked glycosylations40; 41 that exist 
in the mucin domain. Lubricin interacts with biological and non-biological surfaces, and has a 
preponderance to interact with hydrophobic surfaces42; 43. The results support a partitioning of 
lubricin that is cartilage bound and unbound within the SF. Partitioning provides a reservoir of 
lubricin44 that can replace lubricin that is sacrificially worn away during articulation45. This is 
supported by the high amounts of 131I-rhPRG4 recovered from cartilage surfaces with irrigation 
soon after IA delivery, and from SF recovered from closed joint needle aspiration; suggesting that 
131I-rhPRG4 was tethered but not fully adherent to the cartilage surface. These observations 
support the two-compartment pharmacokinetic elimination model. The t1/2of 11.28 hrs reflects 
rhPRG4 that is primarily metabolized in SF which is contained within the diarthrodial joint 
structure. Comparatively less radiolabel was detected in the blood, liver, urine or proximal lymph 
node after IA injection. The t1/2 of 4.81 days is reflective of lubricin that was likely cartilage, 
meniscii and synovial surface bound. These estimates are driven by the tissues only model in Fig 
3b which accounted for 33% of total radioactivity.  Both half-lives are in fair agreement with a 
prior effort24 in medial meniscectomized rat knees that were injected with 131I-truncated rhPRG4 
3 weeks later. In that study, a three-compartment model best fit the PRG4 concentration-time 
profiles and reported ,  and  half-life estimates of 4.5 hrs, 1.5 days and 2.1 weeks respectively. 
We were unable to fit a three compartment model with our data which may be due to lack of 
sampling times past 20 days. Considering counts from the SF exclusively lengthened t1/2 to 28 
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days which is in agreement with the earlier rat study24. The long t1/2 in SF and the fact that K21 > 
K12 (Table 1) suggests that SF is the reservoir for PRG4 and that rhPRG4 may emulate its 
biophysical and physisorptive activity. 
 
In comparing these two studies it is important to realize that the present effort used a larger joint 
and a full-length recombinant human lubricin that was 1404 amino acids long which may have a 
longer residence time. The present study was accomplished with an arthroscope to transect the 
ACL ligament, thus reducing tissue injury associated with an arthrotomy. Use of a minimally 
invasive surgical technique, and delay in treatment, are approaches that recapitulate current clinical 
practice. We also observed in Figs 4-5 that the tibial cartilage surfaces showed a disproportionate 
loss of rhPRG4 over time compared to the femoral cartilage. Since cartilage thinning following 
ACL injury is predicted to be more severe in tibial cartilage and in the medial compartment46, we 
posit if friction-induced metabolic changes in cartilage can confound rhPRG4, PRG447 and Prg448 
in serving its chondroprotective role. 
 
The introduction of rhPRG4 into an injured joint may have several positive consequences. Local 
PRG4 expression is upregulated by physical activity49. The combination of compression and shear 
in vitro has been observed to increase expression of PRG4 by several laboratories45; 50; 51. Human 
recombinant PRG4 also displays anti-inflammatory properties through inhibition of the innate 
immunity receptors, TLR2 and TLR4 52; 53. Suppressing inflammation by itself may play a positive 
role since incubation of bovine cartilage explants with IL-1 in vitro has been shown to suppress 
native PRG4 expression25. Figures 6 and 7 together support the notion that rhPRG4 densely coated 
cartilage surfaces on days 1 and 3 post injection and subsequently diminished over time. Some of 
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
18 
This article is protected by copyright. All rights reserved 
 
the rhPRG4 may have penetrated into the cartilage25 which is supported by the continued 
radioactivity of cartilage despite surface irrigation. By post-injection days 6 and 13 resident 
porcine chondrocyte PRG4 expression was qualitatively supported by chondrocyte 
immunoreactivity (Figure 7). We posit that the presence of rhPRG4 served to restore the 
expression of native PRG4 in an inflammatory environment that was down trending as a result of 
the ACL transection surgery 5 days previous. 
 
The cartilage surface area of the human knee is 121 cm2 54 and 277 cm2 55 for the synovium. The 
cartilage surface area in the Yucatan mini-pig was 32.4 cm2. Availability for rhPRG4 binding is 
thus allometrically 3.7 times larger in the human joint. The 4 mg dose used in the present study 
was effective in mitigating PTOA in the same porcine species following DMM when used weekly 
over three weeks12. A dose escalated single injection study is planned and supported by a recent 
study in the rat where a single 260 g/kg IA rhPRG4 dose, was equally effective to smaller 
repetitive doses10. Extrapolating the distribution of availability based on cartilage surface area 
alone in the human knee from the mini-pig knee leads to the conclusion that a 14.8 mg dose of 
rhPRG4 provided shortly after an acute knee injury may be enough to achieve both cartilage 
surface coverage and bioavailability from SF. This calculation does not consider the much larger 
synovial membrane area. The synovium demonstrated considerable radioactive counts suggesting 
that rhPRG4 was present. Uptake of biomaterials and biologics occurs across synovial villi26, and 
is a source of PRG4 synthesis56 that is under autoregulation52. The present study did not involve 
HA to take advantage of possible synergistic effects with PRG418; 30; 57-60. We observed 
immunopositivity for PRG4 only in the synovium at time 0 (data not shown) but in the absence of 
a non-injected surgical control animal we cannot conclude if this represents a lack of porcine PRG4 
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contribution from the synovium. 
 
Limitations include the application of rhPRG4 early in a PTOA animal model in which disease 
progression was not studied histologically. A relatively low amount of joint cavity irrigation was 
used during arthroscopy. Irrigation has been shown to eliminate the resident lubricin in the bovine 
joint61. The lower amounts of irrigation used for this surgical injury may have resulted in the 
rhPRG4 mixing with resident porcine PRG4 which could impact its bioavailability. By contrast, 5 
days after surgery also likely diminished resident porcine PRG4 levels25. However, an increase in 
native PRG4 expression from the synovium as observed in an equine OA model, 20 days following 
surgery62 has not been excluded. Our study was conducted cumulatively across 3 groups of animals 
due to logistical challenges. Tissues that were recovered in the first group were not retained for 
later histological analysis; a limitation corrected for most of the animals. Finally, this study was 
conducted in quadrupeds that have a different gait pattern than humans and were not skeletally 
mature. However, ACL transection recapitulates a common joint injury in adolescent humans. 
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Legends 
 
Figure 1. Timeline of Yucatan mini-pig pharmacokinetic (PK) study of intra-articular (IA) I131-
rhPRG4 at Day 0 (D0) following ACL transection 5 days prior (D-5). The remaining number of 
porcine following each tissue harvest time point is illustrated. The first harvest involving 5 animals 
occurred at 10 mins following IA (D0+10m) which served as time zero in PK calculations. 
Sequential tissue harvests following IA were conducted at 24 hrs (D1), 72 hrs (D2), 6 days (D6), 
13 days (D13) and 20 days (D20). At each time point synovium and cartilage collected from each 
joint compartment and both condyles were weighed and counted for radioactivity across 21 
animals. Samples of SF, blood, liver and proximal lymph node were also collected and counted. 
Three animals were removed from the analysis as they did not receive IA injection correctly and 
demonstrated very high lymph node radioactivity.  
 
Figure 2. Cartilage surface area and volume analysis by microCT. Four previously frozen 
unoperated Yucatan mini-pig left knee joints served as controls to determine the surface area and 
volume of each cartilage surface from the patellofemoral joint and both compartments of the 
tibiofemoral joint. The product of the tissue density multiplied by the representative cartilage 
volume from each area was used as the tissue mass denominator in normalizing gamma counts per 
tissue weight to determine the total amount of I131-rhPRG4 resident in each cartilage surface. Mean 
± SD is reported. 
 
Figure 3. Least squares fitting model and Akaike Information Criterion (AIC) of the percent of 
total dose of I131-rhPRG4 in recovered knee tissue counts including lavage and aspirated SF across 
time points at 10 minutes, days 1,3,6,13 and 20 for 18 porcine following intra-articular I131-
rhPRG4 delivered 5 days after ACL transection. A) 98% of the total dose at 10 minutes (day 0) 
was accounted for across the 6 time points by least squares elimination profile which did not 
conform to a predicted AIC two-compartment model. B) 33% of the total dose at 10 minutes was 
accounted for by considering only knee tissue counts (excluding lavage and aspirated SF) which 
conformed to an AIC two-compartment model. D) Akaike Information Criterion parameter tables 
showing AIC t1/2 estimates in days, and coefficient of variation (CV%).  Error bars are mean ± SE;  
N=3 at each sampling time. 
 
Figure 4. Knee joint tissue concentrations of I131-rhPRG4 at 10 minutes (day 0), days 1 and 3 (A), 
and days 6,13 and 20 (B). Tibial cartilage and synovial membrane surfaces appeared to contain 
relatively larger amounts of I131-rhPRG4 at 10 minutes and remained greater by days 1,3 and 6 for 
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synovial surfaces. By day 13 and 20, cartilage surfaces showed greater relative  amounts of I131-
rhPRG4.  Abbreviations: Medial femoral condyle (MFC), medial tibial plateau (MTP), lateral 
femoral condyle (LFC), lateral tibial plateau (LTP), medial meniscus (MM), lateral meniscus 
(LM), synovial membrane anterior compartment (SMAC) and synovial membrane posterior 
compartment (SMPC). Error bars are mean ± SE; N=3 at each sampling time. 
 
Figure 5. Percent of recovered total knee I131-rhPRG4 across time points at 10 minutes (day 0), 
days 1,3,6,13 and 20 in 18 porcine following intra-articular I131-rhPRG4 delivered 5 days after 
ACL transection. (A) Comparison of total femoral and tibial cartilage and (B) total medial and 
lateral cartilage. Initially I131-rhPRG4 localized more to the medial joint compartment and tibial 
cartilage surfaces. Towards the end of the concentration-time profiles studied at day 20, the lateral 
joint compartment and femoral cartilage retained a greater relative percentage of recoverable I131-
rhPRG4. Error bars are mean ± SE; N=3 at each sampling time. 
 
Figure 6. Densitometry of rhPRG4 (MW~300 kDa) and native porcine PRG4 (MW~180 kDa) 
bands on Western blots of joint surface lavage in 12 of the 18 porcine following intra-articular I131-
rhPRG4 delivered 5 days after ACL transection. A) Samples at 10 minutes (day 0) (N=3),1 (N=3), 
3 (N=2), 6 (N=1), 13 (N=2) and 20 (N=1) were analyzed on SDS-PAGE and transferred to 
nitrocellulose 4 months following recovery to allow sufficient radioactive decay. Blots were 
probed with polyclonal antibody 1752 and densitometry was performed in triplicate and 
normalized against a 10 g/ml preparation of rhPRG4. B) rhPRG4 decreased over time and was 
detectable up to 13 days later, whereas porcine PRG4 increased over that same interval. Error bars 
are mean ± SD. 
 
Figure 7. Immunohistochemistry of total PRG4 comprising injected rhPRG4 and native PRG4 
across representative porcine at 10 minutes (day 0), days 1,3,6,13 and 20  following intra-articular 
I131-rhPRG4 delivered 5 days after ACL transection in 18 porcine. Cartilage surface 
immunoprobing with monoclonal antibody 9G3 was counterstained with DAPI in sections from 
the two apposing surfaces from medial and lateral joint compartments. Cartilage surface staining 
was qualitatively most intense at day 1 and 3, and least intense by day 20 which is similar to 
untreated and historical control porcine cartilage. Chondrocyte positivity for PRG4 (white arrows) 
appeared most intense at day 6 and may be indicative of renewed native expression of porcine 
PRG4.  
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Table 1. Summary of Fitted Two Compartment Model by Tissue and Fluid Type 
 
Tissue(s) and/or Synovial Fluid or 
Lavage  
t1/2, 
(Days) 
t1/2,β 
(Days) 
K12 
(Day-1) 
K21 
(Day-1) 
Synovial Fluid  0.26 28.07 0.034 0.062 
Anterior & Posterior Synovium  0.59 3.09 0.104 0.253 
Cartilage + Meniscii   0.36 7.10 0.443 0.149 
Cartilage + Meniscii + Cartilage 
Lavage  
0.22 6.19 0.450 0.130 
Cartilage + Meniscii + Cartilage 
Lavage + Anterior & Posterior 
Synovium 
0.33 4.40 0.299 0.186 
Cartilage + Meniscii + Anterior & 
Posterior Synovium 
0.47 4.81 0.252 0.179 
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Figure 2 
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Figure 3 
  
 
 
  
 A
cc
ep
te
d
  A
rt
ic
le
 
 
 
 
 
 
 
 
 
 
 
 
31 
This article is protected by copyright. All rights reserved 
 
 
Figure 4 (A) 
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Figure 4(B) 
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Figure 5(A) 
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Figure 5(B) 
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Figure 6(A) 
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Figure 6(B) 
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Figure 7 
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